scholarly journals Assessing the utilization of radiotherapy near end of life at a Finnish University Hospital: a retrospective cohort study

2017 ◽  
Vol 56 (10) ◽  
pp. 1265-1271 ◽  
Author(s):  
Liisa K. Rautakorpi ◽  
Johanna M. Mäkelä ◽  
Fatemeh Seyednasrollah ◽  
Anna M. Hammais ◽  
Tarja Laitinen ◽  
...  
Keyword(s):  
Cohort Study ◽  
End Of Life ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
University Hospital

scholarly journals Palliative Sedation in COVID-19 End-of-Life Care. Retrospective Cohort Study

Medicina ◽  
2021 ◽  
Vol 57 (9) ◽  
pp. 873
Author(s):  
Jose-Manuel Ramos-Rincon ◽  
Oscar Moreno-Perez ◽  
Nazaret Gomez-Martinez ◽  
Manuel Priego-Valladares ◽  
Eduardo Climent-Grana ◽  
...  
Keyword(s):  
Cohort Study ◽  
End Of Life ◽  
Median Time ◽  
Retrospective Cohort Study ◽  
End Of Life Care ◽  
Retrospective Cohort ◽  
Palliative Sedation ◽  
University Hospital ◽  
Life Care ◽  
Butyl Bromide

Background and Objectives: Descriptions of end-of-life in COVID-19 are limited to small cross-sectional studies. We aimed to assess end-of-life care in inpatients with COVID-19 at Alicante General University Hospital (ALC) and compare differences according to palliative and non-palliative sedation. Material and Methods: This was a retrospective cohort study in inpatients included in the ALC COVID-19 Registry (PCR-RT or antigen-confirmed cases) who died during conventional admission from 1 March to 15 December 2020. We evaluated differences among deceased cases according to administration of palliative sedation. Results: Of 747 patients evaluated, 101 died (13.5%). Sixty-eight (67.3%) died in acute medical wards, and 30 (44.1%) received palliative sedation. The median age of patients with palliative sedation was 85 years; 44% were women, and 30% of cases were nosocomial. Patients with nosocomial acquisition received more palliative sedation than those infected in the community (81.8% [9/11] vs 36.8% [21/57], p = 0.006), and patients admitted with an altered mental state received it less (20% [6/23] vs. 53.3% [24/45], p = 0.032). The median time from admission to starting palliative sedation was 8.5 days (interquartile range [IQR] 3.0–14.5). The main symptoms leading to palliative sedation were dyspnea at rest (90%), pain (60%), and delirium/agitation (36.7%). The median time from palliative sedation to death was 21.8 h (IQR 10.4–41.1). Morphine was used in all palliative sedation perfusions: the main regimen was morphine + hyoscine butyl bromide + midazolam (43.3%). Conclusions: End-of-life palliative sedation in patients with COVID-19 was initiated quite late. Clinicians should anticipate the need for palliative sedation in these patients and recognize the breathlessness, pain, and agitation/delirium that foreshadow death.

scholarly journals Comment on Ramos-Rincon et al. Palliative Sedation in COVID-19 End-of-Life Care. Retrospective Cohort Study. Medicina 2021, 57, 873

Medicina ◽  
2022 ◽  
Vol 58 (1) ◽  
pp. 82 ◽  
Author(s):  
Robert Geoffrey Twycross ◽  
Aaron Kee Yee Wong ◽  
Bella Vivat
Keyword(s):  
Cohort Study ◽  
End Of Life ◽  
Retrospective Cohort Study ◽  
End Of Life Care ◽  
Retrospective Cohort ◽  
Palliative Sedation ◽  
University Hospital ◽  
Life Care ◽  
Medical Wards

We read with interest the article by Ramos-Rincon and colleagues about patients with COVID-19 dying in acute medical wards in a Spanish University hospital [...]

scholarly journals End-of-life chemotherapy use at a Finnish university hospital: a retrospective cohort study

2017 ◽  
Vol 56 (10) ◽  
pp. 1272-1276 ◽  
Author(s):  
Liisa K. Rautakorpi ◽  
Fatemeh Seyednasrollah ◽  
Johanna M. Mäkelä ◽  
Outi M. Hirvonen ◽  
Tarja Laitinen ◽  
...  
Keyword(s):  
Cohort Study ◽  
End Of Life ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
University Hospital

scholarly journals Diabetes Mellitus as a Risk Factor for Drug Resistance Tuberculosis: A Retrospective Cohort Study at King Abdul Aziz University, Jeddah

2021 ◽  
pp. 136-145
Author(s):  
Sumyia Mehrin M. D. Abulkalam ◽  
Mai Kadi ◽  
Mahmoud A. Gaddoury ◽  
Wallaa Khalid Albishi
Keyword(s):  
Diabetes Mellitus ◽  
Drug Resistance ◽  
Risk Factor ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
University Hospital ◽  
P Value ◽  
Baseline Characteristic ◽  
Drug Resistant

Background: The association between tuberculosis (TB) and diabetes mellitus (DM) is re-emerging with the epidemic of type II diabetes. Both TB and DM were of the top 10 causes of death.[1] This study explores diabetes mellitus as a risk factor for developing the different antitubercular drug-resistant (DR) patterns among TB patients.  Methods: A retrospective cohort study has been conducted on all TB cases reported to the King Abdul Aziz University Hospital, Jeddah, between January 2012 to January 2021. All culture-confirmed and PCR-positive TB cases were included in this study. Categorical baseline characteristic of TB patient has been compared with DM status by using Fisher's exact and Pearson chi-square test. The univariable and multivariable logistic regression model was used to estimate the association between DM and different drug resistance patterns.  Results: Of the total 695 diagnosed TB patients, 92 (13.24%) are resistant to 1st line anti TB drugs. Among 92 DR-TB patients, 36 (39.13%) are diabetic. The percentage of different patterns of DR-TB with DM, in the case of mono DR (12.09%), poly DR (4.19%) MDR (0.547%). As a risk factor, DM has a significant association with DR-TB, mono drug-resistant, and pyrazinamide-resistant TB (P-value <0.05). The MDR and PDR separately do not show any significant association with DM, but for further analysis, it shows a significant association with DM when we combined.  Conclusion: Our study identified diabetes mellitus as a risk factor for developing DR-TB. Better management of DM and TB infection caring programs among DM patients might improve TB control and prevent DR-TB development in KSA.

Sign in / Sign up

Export Citation Format

Share Document